SynAct Pharma prepares phase III trial discussion with FDA
SynAct Pharma presented post-hoc analysis of its phase IIb ADVANCE rheumatoid arthritis study using resomelagon, addressing placebo responses and reinforcing its therapeutic profile. The company is preparing to discuss phase III trial design with the FDA.